Adult Dosing
Hyperlipidemia, Mixed Dyslipidemia, Hypertriglyceridemia, Primary Dysbetalipoproteinemia (Type III hyperlipoprotenemia), slowing the progression of atherosclerosis, and primary prevention of cardiovascular disease
- Start 10 mg PO qd, then adjust q2-4 wks depending on lipid levels
- Range: 5-40 mg qd. Max: 40 mg/day
- If on lopinavir/ritonavir or gemfibrozil: Max: 10 mg/day
- Start at 5 mg PO qd if:
- age >65 yrs
- Hypothyroidism
- Asian race
- Taking cyclosporine
Homozygous Familial hypercholesterolemia
- Start 20 mg PO qd, then adjust according to pre-apheresis LDL-C levels
- Range: 5-40 mg PO qd. Max: 40 mg/day
- If on lopinavir/ritonavir or gemfibrozil: Max: 10 mg/day
- Start at 5 mg PO qd if:
- age >65 yrs
- Hypothyroidism
- Asian race
- Taking cyclosporine
Note: Reserve 40 mg dose for patients who have not achieved LDL-C goal with 20 mg dose
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- Severe renal impairment CrCl < 30 mL/min, not on hemodialysis: Start 5 mg PO qd. Max: 10 mg/day
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined, caution advised
- Active liver disease or unexplained increases in LFTs: Contraindicated
- Myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with the therapy. Use with caution in patients with predisposing factors for myopathy. Suspend if markedly elevated creatinine kinase levels occur or if myopathy is diagnosed or suspected
- Rosuvastatin may cause increase in serum transaminases. Perform liver enzyme tests before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically thereafter
- Use with caution when given in conjunction with anticoagulants like Coumarin because this may cause potentiation of the effect of coumarin-type anti-coagulants in prolonging the prothrombin time/INR
- Dipstick-positive proteinuria and microscopic hematuria have been reported with therapy. Consider dose reductions for patients with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
- Caution advised when administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones
- Based on clinical trial data the therapy may increase HbA1c and fasting serum glucose levels and in few instances these increases may exceed the threshold for the diagnosis of diabetes mellitus
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Alcohol use
- Hypothyroidism
- Concomitant coumarin anticoagulant use
- Lopinavir/ritonavir or cyclosporine use
- Concommitant lipid lowering agent use
- Geriatric population
Pregnancy Category:X
Breastfeeding: Since rosuvastatin can cause disruption of infant lipid metabolism, breastfeeding is not recommended. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 12 January 2011). Manufacturer advises that nursing women should not nurse their infants.
Pricing data from www.DrugStore.com in U.S.A.
- Crestor 20 MG TABS [Bottle] (ASTRAZENECA)
30 mg = $155.98
90 mg = $435.99 - Crestor 5 MG TABS [Bottle] (ASTRAZENECA)
30 mg = $154.99
90 mg = $426.96 - Crestor 40 MG TABS [Bottle] (ASTRAZENECA)
30 mg = $155.99
90 mg = $435.95 - Crestor 10 MG TABS [Bottle] (ASTRAZENECA)
30 mg = $154.99
90 mg = $426.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
